Akeso, Inc. Doses First Patient in Phase III Perioperative Study of Cadonilimab in Colon Cancer

Akeso, Inc. (9926.HK) announced that the first patient has been dosed in a Phase III clinical study (COMPASSION-40/AK104-313). This study is evaluating cadonilimab, a first-in-class PD-1/CTLA-4 bispecific antibody, as a monotherapy for the neoadjuvant/adjuvant (perioperative) treatment of resectable microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) colon cancer. This marks the 13th Phase III/registrational study globally for cadonilimab.